Belldegrun Rebecka 4
4 · Kronos Bio, Inc. · Filed Oct 16, 2020
Insider Transaction Report
Form 4
Kronos Bio, Inc.KRON
Belldegrun Rebecka
Director
Transactions
- Conversion
Series A Preferred Stock
2020-10-14−228,315→ 0 total(indirect: By Trust)→ Common Stock (240,872 underlying) - Conversion
Common Stock
2020-10-14+182,866→ 438,703 total(indirect: By Trust) - Conversion
Common Stock
2020-10-14+240,872→ 679,575 total(indirect: By Trust) - Conversion
Series Seed Preferred Stock
2020-10-14−173,333→ 0 total(indirect: By Trust)→ Common Stock (182,866 underlying)
Footnotes (2)
- [F1]Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
- [F2]The reporting person is the beneficiary of Bellco Legacy II Trust ("Bellco") and her husband, Dr. Arie Belldegrun, currently serves as the trustee of Bellco.